The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

U.S. kindergarten vaccination rates inched down again last year and the proportion of children with exemptions rose to an all ...

Segment operating income2 in the second quarter of 2025 was $172 million and segment operating margin2 was 5.6%, compared to $203 million and 6.8%, respectively, in the second quarter of 2024. The ...

Diversified global manufacturer Asahi Kasei will supply its Aqualyzer™-C3 containerized 1 MW-class alkaline-water ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

The Business Research Company The Business Research Company's Generative Artificial Intelligence AI In Engineering Global Market Report 202 ...

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of C3.ai's market ...

C3.ai announced today that CEO Tom Siebel would be stepping down and that the company was in the process of looking for its ...

C3 AI founder and Chief Executive Officer Tom Siebel today announced that he will step down because of health issues.